A multidisciplinary group of international experts has released recommendations for the use of biologics in patients with systemic lupus erythematosus.
The Sjögren's Syndrome Foundation has released the first clinical practice guidelines for the disease, which includes recommendations on the management of fatigue, inflammatory musculoskeletal pain, and use of biologic agents.
Most patients required a least a year to completely withdraw from immunotherapy in order to demonstrate a clinical remission.
Clinical Pain Advisor Articles
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Electroacupuncture May Help Reduce Opioid Use in Chronic Musculoskeletal Pain
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Predicting Pain Chronicization After Spine Surgery
- Chronic Low Back Pain Levels Vary Between Sex and Race
- FDA Approval of Medication With a Digital Monitoring System: Major Breakthrough or "Brave New World"?
- Errors in Clinical Notes Generated by Speech Recognition Are Not Uncommon
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?